A synthetic lipid-lowering agent. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Pravastatin lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)

prav, eptastatin, [1s-[1alpha(betas*,deltas*),2alpha,6alpha,8beta(r*),8aalpha]]-1,2,6,7,8,8a-hexahydro-beta,!d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic acid, pravastatine, pravastatin (substance), pravastatina, pravastatin, pravastatin acid, pravastatin, 1-naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1s-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(r*),8aalpha))-, pravastatin [chemical/ingredient], (+)-(3r,5r)-3,5-dihydroxy-7-[(1s,2s,6s,8s,8ar)-6-hydroxy-2-methyl-8-{[(s)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid, pravastatinum, pravastatin (product)

C62070

F-618F4